Menu
Former Director General of the ABPI, Prof Jones has occupied a number of roles as a member of several distinguished agencies, including the Medicines Commission, an adviser to the Cabinet Office on the Human Genome project 2001, the Prime Minister’s Task Force on the Competitiveness of the Pharmaceutical Industry (PICTF) and Chair of the Government Advisory Group on Genetics Research. From 2003-2005 he was a Commissioner at the World Health Organisation (WHO) on the Commission for Intellectual Property, Innovation and Public Health (CIPIH).
A clinical neuroscientist and integrative medicine practitioner who founded a consultancy specialising in brain health, the endocannabinoid system and phytocannabinoids including CBD and medicinal cannabis. Dr Philipps’ focus includes translational research and clinical and industry education around the body’s endocannabinoid system and cannabinoid product, with particular emphasis on the use of cannabinoid medicine for traumatic brain injuries in professional sports.
Dr Bhatarah has over 20 years’ experience within the international pharmaceutical industry & regulatory environment. She has 12 years’ experience in the Medicinal Cannabis industry, covering everything from cultivation to FDA approval of finished medicinal products, and has expertise in product development for clinical trials, commercial launch, technology transfer and manufacturing.
Dr Andy Yates has spent 25 years in pharma and biotech, working in R&D, medical affairs, commercial, business development and strategy functions. He serves as Chief Scientific Officer at Artelo Biosciences and has extensive experience in all aspects of medicine development programmes including three cannabinoid-based medicines within Artelo’s portfolio. He is also a UK pharmacist who received his PhD in cannabinoid medicinal chemistry from the University of Nottingham.
Dr Andrew Bradford has extensive experience of medical cannabis having worked at The Medical Cannabis Clincs, Lyphe and the Medical Rehabilitation Clinic managing patients with neurological conditions and disability. He is a neuro-rehabilitation specialist and was a consultant at Walkergate Park Centre for Neuro-rehabilitation and Neuro-psychiatry in Newcastle. He was previously involved in stroke research in Glasgow. He has an interest in psychological medicine having completed an MSc in positive psychology and has training in Human Givens therapy. Furthermore, he has additional experience in primary care, drug dependence, and secure unit medicine in the UK.
Greer Deal is a Fellow of the Chartered Management Institute and a Member of The Organisation for Professionals in Regulatory Affairs, with over 25 years’ experience in the life sciences sector covering regulatory affairs, medical information, pharmacovigilance, product development, compassionate use programmes and plant derived products. She is currently Director of Global Regulatory Services, which focuses on regulatory affairs and quality compliance, and frequently speaks at seminars on changing regulations for medical device companies in Europe.
Dr Paul Duffy is senior project toxicologist with expertise in new modalities, including RNA therapeutics and regenerative medicines. He is a highly experienced project toxicologist with submission experience in multiple territories, including repurposing of existing drug projects for new applications. He has served on the BTS Executive Committee since 2006, is widely published in peer reviewed journals, and previously worked as Senior Project Toxicologist at AstraZeneca and as Board Member for Stem Cells for Safer Medicines.
The purpose of the MCA Council (The Council) is to provide our management team with guidance and advice on how to best support the delivery of our strategy.
Chaired by a nominee of our members The Council ensures that the views of our members are reflected in our decision-making processes. To achieve this, we invite each member to nominate a representative to serve for a minimum of 12 months to help challenge our views, and assist us in an advisory capacity.
Meetings of the Council will be held bi-monthly with every second meeting being convened as a face-to-face meeting.
At the inaugural meeting terms of reference for The Council will be agreed upon.
Steve Moore is Founder and Strategic Counsel for the MCA with 25 years experience of working in social change and political campaigns, including working with Charlotte Caldwell to reform policy relating to the access of medicinal cannabis. He was formerly Chief Executive of David Cameron’s Big Society Network and has curated change programmes for Channel 4 Television, the Royal Society of Arts and PwC.
Zehra Zahir has worked in executive roles across the public and private sector, specialising in organisational change and risk management. She has achieved Graduate Chartership status with the British Psychological Society and is a qualified PMP project manager.
Bill Griffin has worked in corporate communications for over 25 years across multiple sectors including healthcare, banking, travel and telecommunications.
Roisin Delaney is a marketing professional with a decade of experience working in business media, across health and wellbeing. She also provides communications services for brands navigating complex regulatory frameworks and advertising restrictions.
Jimmy Nicholls has been a journalist for a decade, lately specialising in the impact of CBD regulation on food and drink. He has previously written about corporate governance, financial regulation and local government.
Jacob Elms has spent a decade studying the cannabis industry and the impact of cannabinoids on the human body. He has a degree in business management, specialising in ethical leadership in a changing world.